OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.292
EU - Europa 5.330
AS - Asia 5.189
SA - Sud America 808
AF - Africa 169
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 12
Totale 20.833
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.113
SG - Singapore 1.546
IT - Italia 1.411
CN - Cina 1.298
GB - Regno Unito 963
IE - Irlanda 833
VN - Vietnam 643
HK - Hong Kong 617
BR - Brasile 587
DE - Germania 512
SE - Svezia 368
FR - Francia 252
RU - Federazione Russa 208
FI - Finlandia 204
IN - India 175
ID - Indonesia 147
KR - Corea 142
UA - Ucraina 113
TR - Turchia 94
CA - Canada 89
AR - Argentina 77
BD - Bangladesh 69
JP - Giappone 66
BG - Bulgaria 63
IQ - Iraq 63
NL - Olanda 61
MX - Messico 53
PL - Polonia 51
LT - Lituania 44
ES - Italia 42
TW - Taiwan 41
CO - Colombia 40
CL - Cile 36
ZA - Sudafrica 35
EG - Egitto 34
PK - Pakistan 34
AU - Australia 30
BE - Belgio 30
CZ - Repubblica Ceca 30
MY - Malesia 29
EC - Ecuador 27
AE - Emirati Arabi Uniti 25
AT - Austria 25
IR - Iran 23
MA - Marocco 23
SA - Arabia Saudita 21
VE - Venezuela 19
JO - Giordania 18
KE - Kenya 18
NP - Nepal 18
RO - Romania 18
PH - Filippine 15
TH - Thailandia 14
CH - Svizzera 13
MD - Moldavia 12
UZ - Uzbekistan 11
AZ - Azerbaigian 10
EU - Europa 10
PY - Paraguay 10
SY - Repubblica araba siriana 10
TN - Tunisia 10
DO - Repubblica Dominicana 9
HU - Ungheria 9
IL - Israele 9
BH - Bahrain 7
DZ - Algeria 7
GR - Grecia 7
JM - Giamaica 7
AL - Albania 6
CR - Costa Rica 6
NG - Nigeria 6
PT - Portogallo 6
RS - Serbia 6
AO - Angola 5
ET - Etiopia 5
GH - Ghana 5
HN - Honduras 5
HR - Croazia 5
KG - Kirghizistan 5
LB - Libano 5
MT - Malta 5
PE - Perù 5
SK - Slovacchia (Repubblica Slovacca) 5
BO - Bolivia 4
CI - Costa d'Avorio 4
CY - Cipro 4
DK - Danimarca 4
GA - Gabon 4
LV - Lettonia 4
NO - Norvegia 4
PS - Palestinian Territory 4
SI - Slovenia 4
IS - Islanda 3
KH - Cambogia 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
Totale 20.788
Salva come PNG Salva come JPEG
Città #
Ashburn 1.089
Singapore 1.020
Santa Clara 986
Dublin 828
Fairfield 636
Chandler 592
Hong Kong 591
Dallas 471
San Jose 423
Southend 420
Hefei 337
Houston 299
Woodbridge 294
Beijing 275
Nyköping 259
Seattle 254
Wilmington 240
Ann Arbor 227
Dearborn 215
London 211
Ho Chi Minh City 204
Council Bluffs 188
New York 177
Cambridge 176
Los Angeles 175
Helsinki 166
Modena 155
The Dalles 150
Jacksonville 146
Hanoi 143
Seoul 132
Chicago 126
Jakarta 110
Munich 107
Milan 93
Shanghai 93
Lauterbourg 89
Bologna 74
San Diego 74
Moscow 73
Rome 70
Fremont 62
Sofia 61
Princeton 60
Frankfurt am Main 57
Redwood City 52
São Paulo 52
Orem 51
Tokyo 46
Eugene 44
Dong Ket 41
Salt Lake City 40
Warsaw 39
Baghdad 38
Izmir 37
Bremen 33
Buffalo 33
Guangzhou 33
Enfield 32
Parma 30
Phoenix 30
Reggio Emilia 30
Columbus 29
Mumbai 29
San Giuliano Milanese 26
Da Nang 25
Elk Grove Village 25
Falls Church 25
Paris 25
Brooklyn 24
Portsmouth 24
Redondo Beach 24
Tampa 23
Toronto 23
Lawrence 22
Nuremberg 22
Asyut 21
Brussels 21
Chennai 19
Denver 19
Haiphong 19
Amsterdam 18
Dhaka 18
Johannesburg 18
Kent 18
Santiago 18
Poplar 17
Turku 17
Atlanta 16
Montreal 16
Belo Horizonte 15
Brno 15
Cardiff 15
Des Moines 15
Düsseldorf 15
Florence 15
Madrid 15
Mexico City 15
Nairobi 15
Rio de Janeiro 15
Totale 14.040
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 592
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 444
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 394
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 387
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 378
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 377
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 374
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 372
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 368
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 356
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 352
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 348
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 342
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 341
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 323
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 321
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 320
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 315
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 314
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 305
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 305
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 303
Immune characterization of breast cancer metastases: prognostic implications. 300
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 299
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 299
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 297
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 292
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 291
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 289
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 287
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 280
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 278
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 274
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 273
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 268
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 263
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 263
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 261
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 257
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 254
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 253
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 250
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 244
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 244
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 242
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 242
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 241
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 231
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 229
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 229
The role of exosomes in breast cancer diagnosis 228
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 222
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 222
Lapatinib and renal impairment: a case report 221
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 218
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 209
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 208
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 208
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 205
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 204
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 200
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 200
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 199
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 197
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 187
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 182
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 180
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 179
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 177
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 170
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 161
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 158
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 151
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 150
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 146
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 146
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 137
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 134
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 122
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 119
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 97
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 77
Totale 20.975
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.897
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.897
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021478 0 0 0 0 0 0 0 0 0 195 124 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20267.206 567 251 924 798 1.108 510 1.047 441 806 754 0 0
Totale 20.975